Physician profile
Robert Walton Garner
NPI 1285612242
$3,156.47
in general payments reported to CMS, 2019-2025
25 companies · $89.44 in 2025
The $89.44 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $956 · 2020: $683 · 2021: $741 · 2022: $91.63 · 2023: $318 · 2024: $277 · 2025: $89.44.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $684.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $684.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $739.14 | 2020-2025 | |
| Allergan, INC. | $429.27 | 2019-2021 | |
| Lilly USA, LLC | $302.92 | 2019-2024 | Mounjaro |
| Astrazeneca Pharmaceuticals LP | $260.14 | 2019-2024 | Farxiga, Airsupra |
| Novo Nordisk INC | $251.69 | 2019-2024 | Rybelsus, Ozempic |
| Janssen Pharmaceuticals, INC | $169.79 | 2019-2020 | |
| Amgen INC. | $147.39 | 2019-2024 | Repatha, Otezla |
| Pfizer INC. | $140.47 | 2019-2024 | |
| Braintree Laboratories, INC. | $126.63 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $88.69 | 2019-2021 | |
| Stryker Corporation | $72.28 | 2025 | Pangea, Triathlon |
| Boehringer Ingelheim Pharmaceuticals, INC. | $71.34 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $62.89 | 2019-2020 | |
| Sanofi Pasteur INC. | $49.92 | 2019-2020 | |
| Astellas Pharma US INC | $36.26 | 2024 | Veozah |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $34.33 | 2019-2023 | Bexsero, Shingrix |
| Amarin Pharma, INC. | $32.59 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $23.38 | 2019 | |
| Dexcom, INC. | $22.03 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.40 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.54 | 2023 | |
| Nalpropion Pharmaceuticals LLC | $16.86 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $14.86 | 2021 | |
| Currax Pharmaceuticals LLC | $14.22 | 2024 | Contrave |
| Ironwood Pharmaceuticals, INC | $13.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Garner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.